Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

292
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

103
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO NON-AGE-RELATED MACULAR DEGENERATION

Pages

  10-19

Abstract

 Purpose: To report the long-term results of intravitreal BEVACIZUMAB (Avastin) therapy for CHOROIDAL NEOVASCULARIZATION (CNV) secondary to NON-AGE-RELATED MACULAR DEGENERATION (non-AMD).Methods: This prospective interventional case series was conducted on patients with non-AMD CNV. All patients received 1.25 mg intravitreal BEVACIZUMAB and were followed for at least 18 weeks. Indications for retreatment were decreased visual acuity or recurrence of subretinal fluid or hemorrhage associated with leakage on fluorescein angiography. Primary outcome measures were changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT). Secondary outcome measures consisted of any adverse event related to the therapy. Results: The study included 31 eyes of 28 patients with non-AMD CNV including idiopathic (n=11), due to myopia (n=7), angioid streaks (n=5), and other disorders (n=8). Mean initial BCVA was 20/100 which improved to 20/60 at 6 weeks; 20/40 at 12, 18, 24, and 36 weeks; and 20/30 at 54 weeks. Serial optical coherence tomography measurements showed mean CMT of 288 mm at baseline, which was decreased to 209 mm at last visit (P=0.95). There was no correlation between the underlying disease and changes in BCVA during the follow-up period. Conclusion: Intravitreal BEVACIZUMAB significantly improved visual acuity in eyes with non-AMD CNV due to various etiologies.

Cites

  • No record.

    • References

    Cite

    APA: Copy

    SALEHIPOUR, MASOUD, VAFI, N., DOUZANDEH, A., & YASERI, M.. (2010). INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO NON-AGE-RELATED MACULAR DEGENERATION. JOURNAL OF OPHTHALMIC AND VISION RESEARCH, 5(1), 10-19. SID. https://sid.ir/paper/311396/en

    Vancouver: Copy

    SALEHIPOUR MASOUD, VAFI N., DOUZANDEH A., YASERI M.. INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO NON-AGE-RELATED MACULAR DEGENERATION. JOURNAL OF OPHTHALMIC AND VISION RESEARCH[Internet]. 2010;5(1):10-19. Available from: https://sid.ir/paper/311396/en

    IEEE: Copy

    MASOUD SALEHIPOUR, N. VAFI, A. DOUZANDEH, and M. YASERI, “INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO NON-AGE-RELATED MACULAR DEGENERATION,” JOURNAL OF OPHTHALMIC AND VISION RESEARCH, vol. 5, no. 1, pp. 10–19, 2010, [Online]. Available: https://sid.ir/paper/311396/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top